Ratings Hubei Jumpcan Pharmaceutical Co., Ltd.

Equities

600566

CNE0000018X6

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
32.38 ^CNY	-0.92%		-0.31%	+3.02%

Jun. 27	Hubei Jumpcan Pharmaceutical Obtains Drug Registration for Antibiotic Injection; Shares Down 3%	MT
Jun. 20	Hubei Jumpcan Pharmaceutical Gets Drug Registration Certificate for Allergy Drug; Shares Slide 3%	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company's attractive earnings multiples are brought to light by a P/E ratio at 9.79 for the current year.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	+3.02%	4.14B	D+
ELI LILLY AND COMPANY	+54.07%	816B	C+
NOVO NORDISK A/S	+38.59%	634B	B
JOHNSON & JOHNSON	-7.05%	351B	C+
MERCK & CO., INC.	+15.44%	323B	B-
ABBVIE INC.	+5.72%	293B	C+
ASTRAZENECA PLC	+13.40%	238B	B+
ROCHE HOLDING AG	+0.61%	222B	A+
NOVARTIS AG	+13.24%	218B	B-
AMGEN INC.	+7.42%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes